Patent · US Active

Recombinant MVA virus and the use thereof

US8197825B2 · kind B2 · utility

18Cited by

6References

18Claims

0Family size

Assignee

GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH · DE

Inventors

Gerd Sutter · Munich, DE
Marion Ohlmann · Munich, DE
Volker Erfle · Munich, DE

Key dates

Filing date	Jun 14, 2010
Grant date	Jun 12, 2012
Priority date	—
Expiry date	Jun 14, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.